MD Anderson Enters 5-Year Deal With Myriad Genetics To Develop MRD Assay
The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. (MYGN), Tuesday announced a five-year partnership to ...
News Medical4h
Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay
The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular ...
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of ...